Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2004

View Archived Issues

Farnesoid X receptor agonist protects against liver fibrosis

JTE-607 induces cardioprotective effects in a rat model of ischemia and reperfusion

Once-daily mosapride improves constipation in PD patients

Botulinum toxin A shows promise in the treatment of detrusor overactivity

Good efficacy and safety profile found for XP-828L in mild to moderate psoriasis

Novel COX-1 inhibitors prepared and tested at Fujisawa

Novel PPARdelta agonists identified by Bayer researchers

Clinical data support the use of gemifloxacin in AECB

New NO-donating rapamycin derivatives described by NitroMed

Vertex claims new SHP-2 phosphatase inhibitors and their use

Novel aggrecanase/MMP-13 inhibitors under study at Japan Tobacco

Janssen researchers present new PAR-1 antagonists

New cannabinoid CB1/CB2 ligands and their use claimed by AstraZeneca

Potential use of a kappa opioid agonist in abdominal pain of IBS

Neramexane fails to reach statistical significance in phase III Alzheimer's study

NRP-104 given fast track status for treating cocaine dependence

Micrologix Biotech completes acquisition of MitoKor

Chiron acquires Prion Solutions

Satraplatin plus radiation therapy studies in phase I/II trial for NSCLC

Exenatide NDA accepted for review

MGI Pharma to acquire Zycos

MGI Pharma signs definitive merger agreement to acquire Aesgen

MGI Pharma and SuperGen sign license agreement for Dacogen

Positive interim results from phase II trials of TroVax

NDA submission for Aczone

Procleix WNV Assay tested on Procleix TIGRIS System under IND

GlaxoSmithKline acquires Fraxiparine, Fraxodi and Arixtra

Celsion cleared to conduct phase I study of ThermoDox in liver cancer

Clarinex syrup approved for use in children with allergies, hives

Antithrombotic effects of novel coagulation factor Xa inhibitor

Lethal factor inhibitor effective in anthrax infection

Dual protease inhibitor effective against inflammatory processes

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026